Teva Launches Generic Imitrex to Treat Headaches

Teva Pharmaceuticals has launched sumatriptan succinate injection, the generic equivalent of GlaxoSmithKline's Imitrex, in 4 mg and 6 mg dosage strengths.

Teva Pharmaceuticals has launched sumatriptan succinate injection, the generic equivalent of GlaxoSmithKline’s Imitrex, in 4 mg and 6 mg dosage strengths.

The product is self-administered subcutaneously via single-dose, prefilled syringe autoinjector in the back of the arm or outer thigh.

Sumatriptan succinate injection is a selective serotonin receptor agonist indicated to treat acute migraine with or without aura, as well as acute cluster headaches in adults. It may also block other pain pathways in the brain.

About 36 million individuals in the United States suffer from migraines and their associated side effects. The findings of the American Migraine Study II showed that 85% of respondents experienced throbbing pain, 80% experienced sensitivity to light, 76% experienced sensitivity to sound, and 73% experienced nausea.